Search Results - "Shaddinger, Bonnie C."

Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials by Shaddinger, Bonnie C, Xu, Yanmei, Roger, James H, Macphee, Colin H, Handel, Malcolm, Baidoo, Charlotte A, Magee, Mindy, Lepore, John J, Sprecher, Dennis L

“…We explored the theorized upregulation of platelet-activating factor (PAF)- mediated biologic responses following lipoprotein-associated phospholipase A2…”
Get full text

Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus by Shaddinger, Bonnie C., Soffer, Joseph, Vlasakakis, Georgios, Shabbout, Mayadah, Weston, Cindy, Nino, Antonio

“…Compare the efficacy and safety of albiglutide from a ready-to-use, single-dose, auto-injector system with the lyophilized product in patients with type 2…”
Get full text

Effect of Albiglutide on Cholecystokinin‐Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study by Shaddinger, Bonnie C., Young, Malcolm A., Billiard, Julia, Collins, David A., Hussaini, Azra, Nino, Antonio

“…The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) exenatide and lixisenatide reduce cholecystokinin (CCK)‐induced gallbladder emptying in healthy…”
Get full text

Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function by Mahar, Kelly M., Shaddinger, Bonnie C., Ramanjineyulu, Bandi, Andrews, Susan, Caltabiano, Stephen, Lindsay, Alistair C., Cobitz, Alexander R.

“…Daprodustat is a hypoxia‐inducible factor‐prolyl hydroxylase inhibitor in development for treatment of anemia of chronic kidney disease. We evaluated the role…”
Get full text

A Randomized, Double‐Blind, Single‐Dose, Crossover Study to Demonstrate the Bioequivalence of 2 Formulations of Albiglutide in Healthy Adult Participants by Shaddinger, Bonnie C., Vlasakakis, Georgios, Soffer, Joseph, Thorpe, Karl M., Hatch, Daniel, Nino, Antonio J.

“…Albiglutide, developed for treatment of type 2 diabetes mellitus, is provided in a dual‐chamber cartridge (DCC) single‐dose pen‐injector containing lyophilized…”
Get full text

Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, on Arterial Inflammation as Assessed With 18F-Fluorodeoxyglucose-Positron Emission Tomography Imaging by Tawakol, Ahmed, Singh, Parmanand, Rudd, James H.F., Soffer, Joseph, Cai, Gengqian, Vucic, Esad, Brannan, Sarah P., Tarka, Elizabeth A., Shaddinger, Bonnie C., Sarov-Blat, Lea, Matthews, Paul, Subramanian, Sharath, Farkouh, Michael, Fayad, Zahi A.

Get full text

Evaluation of vardenafil and sildenafil on cardiac repolarization by Morganroth, Joel, Ilson, Bernard E, Shaddinger, Bonnie C, Dabiri, Guissou A, Patel, Bela R, Boyle, Duane A, Sethuraman, Venkat S, Montague, Timothy H

“…This novel study evaluated the effects of vardenafil and sildenafil on QT and corrected QT (QTc) duration using a model that minimizes experimental error to…”
Get full text

Platelet Aggregation Unchanged by Lipoprotein-Associated Phospholipase A.sub.2 Inhibition: Results from an In Vitro Study and Two Randomized Phase I Trials by Shaddinger, Bonnie C, Xu, Yanmei, Roger, James H, Macphee, Colin H, Handel, Malcolm, Baidoo, Charlotte A, Magee, Mindy, Lepore, John J, Sprecher, Dennis L

“…Background We explored the theorized upregulation of platelet-activating factor (PAF)- mediated biologic responses following lipoprotein-associated…”
Get full text

Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2Inhibitor, on Arterial Inflammation as Assessed With18F-Fluorodeoxyglucose-Positron Emission Tomography Imaging by Tawakol, Ahmed, Singh, Parmanand, Rudd, James HF, Soffer, Joseph, Cai, Gengqian, Vucic, Esad, Brannan, Sarah P, Tarka, Elizabeth A, Shaddinger, Bonnie C, Sarov-Blat, Lea, Matthews, Paul, Subramanian, Sharath, Farkouh, Michael, Fayad, Zahi A

“…[...]there are reasons to anticipate that a PET analysis that is limited to locations with evident structural atherosclerotic disease (i.e., a plaque-based…”
Get full text

Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, on Arterial Inflammation as Assessed With18 F-Fluorodeoxyglucose-Positron Emission Tomography Imaging by Tawakol, Ahmed, MD, Singh, Parmanand, MD, Rudd, James H.F., PhD, Soffer, Joseph, MD, Cai, Gengqian, PhD, Vucic, Esad, MD, Brannan, Sarah P., DPhil, Tarka, Elizabeth A., MD, Shaddinger, Bonnie C., PharmD, Sarov-Blat, Lea, PhD, Matthews, Paul, MD, Subramanian, Sharath, MD, Farkouh, Michael, MD, Fayad, Zahi A., PhD

Get full text